Cardiff Oncology announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as chief medical officer. Dr. Kabbinavar will oversee the clinical development program for the company’s investigational drug onvansertib and will report directly to CEO, Mark Erlander, PhD.
Published first on TheFly
